PLX Quote, Financials, Valuation and Earnings

Armata Pharmaceuticals has a net margin of 35.65% compared to Protalix BioTherapeutics's net margin of --. Protalix BioTherapeutics's return on equity of 8.75% beat Armata Pharmaceuticals's return on equity of --.

Protalix BioTherapeutics has a consensus price target of $14.50, signalling upside risk potential of 535.97%. On the other hand Armata Pharmaceuticals has an analysts' consensus of $7.00 which suggests that it could grow by 527.8%. Given that Protalix BioTherapeutics has higher upside potential than Armata Pharmaceuticals, analysts believe Protalix BioTherapeutics is more attractive than Armata Pharmaceuticals.

Protalix BioTherapeutics has a beta of 0.456, which suggesting that the stock is 54.351% less volatile than S&P 500. In comparison Armata Pharmaceuticals has a beta of 0.914, suggesting its less volatile than the S&P 500 by 8.595%.

Protalix BioTherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix BioTherapeutics pays -- of its earnings as a dividend. Armata Pharmaceuticals pays out -- of its earnings as a dividend.

Protalix BioTherapeutics quarterly revenues are $18.2M, which are larger than Armata Pharmaceuticals quarterly revenues of --. Protalix BioTherapeutics's net income of $6.5M is higher than Armata Pharmaceuticals's net income of $2.6M. Notably, Protalix BioTherapeutics's price-to-earnings ratio is 76.00x while Armata Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix BioTherapeutics is 3.54x versus 404.15x for Armata Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Inovio Pharmaceuticals has a net margin of 35.65% compared to Protalix BioTherapeutics's net margin of -16566.39%. Protalix BioTherapeutics's return on equity of 8.75% beat Inovio Pharmaceuticals's return on equity of -119.02%.

Protalix BioTherapeutics has a consensus price target of $14.50, signalling upside risk potential of 535.97%. On the other hand Inovio Pharmaceuticals has an analysts' consensus of $7.83 which suggests that it could grow by 434.7%. Given that Protalix BioTherapeutics has higher upside potential than Inovio Pharmaceuticals, analysts believe Protalix BioTherapeutics is more attractive than Inovio Pharmaceuticals.

Protalix BioTherapeutics has a beta of 0.456, which suggesting that the stock is 54.351% less volatile than S&P 500. In comparison Inovio Pharmaceuticals has a beta of 1.837, suggesting its more volatile than the S&P 500 by 83.748%.

Protalix BioTherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inovio Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix BioTherapeutics pays -- of its earnings as a dividend. Inovio Pharmaceuticals pays out -- of its earnings as a dividend.

Protalix BioTherapeutics quarterly revenues are $18.2M, which are larger than Inovio Pharmaceuticals quarterly revenues of $117K. Protalix BioTherapeutics's net income of $6.5M is higher than Inovio Pharmaceuticals's net income of -$19.4M. Notably, Protalix BioTherapeutics's price-to-earnings ratio is 76.00x while Inovio Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix BioTherapeutics is 3.54x versus -- for Inovio Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

NexGel has a net margin of 35.65% compared to Protalix BioTherapeutics's net margin of -27.95%. Protalix BioTherapeutics's return on equity of 8.75% beat NexGel's return on equity of -63.18%.

Protalix BioTherapeutics has a consensus price target of $14.50, signalling upside risk potential of 535.97%. On the other hand NexGel has an analysts' consensus of $6.00 which suggests that it could grow by 129.01%. Given that Protalix BioTherapeutics has higher upside potential than NexGel, analysts believe Protalix BioTherapeutics is more attractive than NexGel.

Protalix BioTherapeutics has a beta of 0.456, which suggesting that the stock is 54.351% less volatile than S&P 500. In comparison NexGel has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Protalix BioTherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NexGel offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix BioTherapeutics pays -- of its earnings as a dividend. NexGel pays out -- of its earnings as a dividend.

Protalix BioTherapeutics quarterly revenues are $18.2M, which are larger than NexGel quarterly revenues of $3M. Protalix BioTherapeutics's net income of $6.5M is higher than NexGel's net income of -$850K. Notably, Protalix BioTherapeutics's price-to-earnings ratio is 76.00x while NexGel's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix BioTherapeutics is 3.54x versus 1.96x for NexGel. Usually stocks with elevated PS ratios are considered overvalued.

Sangamo Therapeutics has a net margin of 35.65% compared to Protalix BioTherapeutics's net margin of -309.84%. Protalix BioTherapeutics's return on equity of 8.75% beat Sangamo Therapeutics's return on equity of -217.48%.

Protalix BioTherapeutics has a consensus price target of $14.50, signalling upside risk potential of 535.97%. On the other hand Sangamo Therapeutics has an analysts' consensus of $5.00 which suggests that it could grow by 696.43%. Given that Sangamo Therapeutics has higher upside potential than Protalix BioTherapeutics, analysts believe Sangamo Therapeutics is more attractive than Protalix BioTherapeutics.

Protalix BioTherapeutics has a beta of 0.456, which suggesting that the stock is 54.351% less volatile than S&P 500. In comparison Sangamo Therapeutics has a beta of 1.570, suggesting its more volatile than the S&P 500 by 57.032%.

Protalix BioTherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sangamo Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix BioTherapeutics pays -- of its earnings as a dividend. Sangamo Therapeutics pays out -- of its earnings as a dividend.

Protalix BioTherapeutics quarterly revenues are $18.2M, which are larger than Sangamo Therapeutics quarterly revenues of $7.6M. Protalix BioTherapeutics's net income of $6.5M is higher than Sangamo Therapeutics's net income of -$23.4M. Notably, Protalix BioTherapeutics's price-to-earnings ratio is 76.00x while Sangamo Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix BioTherapeutics is 3.54x versus 2.20x for Sangamo Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.